Results 141 to 150 of about 81,406 (283)
RNA‐binding protein RBMS1: A new target for cancer diagnosis and treatment
Precision Medical Sciences, EarlyView.This schematic illustrates the diverse regulatory roles of RNA‐binding motif single‐stranded interacting protein 1 (RBMS1) across multiple human cancers. In breast cancer, RBMS1 stabilizes B4GALT1 mRNA to promote PD‐L1 glycosylation, modulating tumor immune escape and immunotherapy efficacy.
Xingda Run +7 more
wiley +1 more source
Journal of UltrasonographyAssessment of features of triple-negative breast cancer (TNBC) and benign breast lesions in multipara-metric ultrasonography, with an emphasis on the added value of sonoelastography.
Gumowska Magdalena +1 more
doaj +1 more source
Precision Medical Sciences, EarlyView.Breast cancer subtypes, estrogen receptor‐positive (ER+), HER2‐enriched, and TNBC, are defined by genomic and epigenetic signatures. Multi‐omics profiling, immunotherapy, liquid biopsy, and AI‐driven radiogenomics enable precision medicine. Tools like Oncotype DX and PAM50 support personalized care.
Samina Malik +4 more
wiley +1 more source
Precision Radiation Oncology, EarlyView.Radiotherapy enhances CAR‐Tcell therapy by increasing antigenicity, improving trafficking, and reshaping the tumor microenvironment. Despite its dual effects, including potential immune suppression, understanding these mechanisms enables the development of strategies to maximize synergy in solid tumors.
Leran Qiu +4 more
wiley +1 more source
Targeting hexokinase 2 to induce breast cancer cell senescence
British Journal of Pharmacology, EarlyView.Background and Purpose Hexokinase 2 (HK2) is a key enzyme linked to high tumour cell proliferation. Its inhibitors such as 3‐bromopyruvic acid (3‐BP) induce cancer cell death, highlighting HK2 modulation as potential anti‐cancer treatment. However, standard chemotherapies often cause the emergence of senescent cancer cells, which goes along with cell ...
Helmut Bischof +8 more
wiley +1 more source
Cancer pain: current practice and emerging targets
British Journal of Pharmacology, EarlyView.Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye +5 more
wiley +1 more source
Update on Menopause Hormone Therapy; Current Indications and Unanswered Questions
Clinical Endocrinology, EarlyView.ABSTRACT Objective To provide clinicians involved in managing menopause with a summary of current evidence surrounding menopause hormone therapy (MHT). Design The authors evaluate and synthesize existing pooled evidence relating to MHT's clinical indications, efficacy, and safety and explore the limitations of existing data. Patients The review focuses
Annice Mukherjee, Susan R. Davis
wiley +1 more source
MYC amplification sensitizes TNBC to CHK1 inhibitors
Cellular SignallingTriple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, for which effective therapy is urgently needed. We demonstrated that MYC overexpression was associated with TNBC subtype and promoted the cell proliferation, invasion and migration in TNBC cells.
Bin, Li +7 more
openaire +2 more sources
Cell Proliferation, EarlyView.Novel curcumin‐derived M4 binds HSP70's ATPase domain, disrupting HSP70‐mediated lysosomes‐autophagy pathway to inhibit TNBC growth and metastasis, and synergizes with paclitaxel for potent combination therapy. ABSTRACT Structural modification of curcumin yielded a novel series of 1,4‐pentadien‐3‐one oxime ether derivatives, among which compound M4 ...
Zijian Li +6 more
wiley +1 more source